Chor-Sang Chim

14PUBLICATIONS
27CO-AUTHORS
PharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Oral and maxillofacial surgeryEpigenetics (incl. genome methylation and epigenomics)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 06, 2025
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).

Jin Seok Kim, Yang Song, Wei-Ying Jen

|Feb 21, 2024
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.

Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang

|Apr 25, 2022
The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.

Hoi Ki Karen Tang, Chi Yeung Fung, Gareth J Morgan

|Sep 03, 2021
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.

Chor Sang Chim, Shaji Kumar, Vincent Kai Chung Wong

|May 28, 2021
miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration.

Min Yue Zhang, Lu Qian Wang, Chor Sang Chim

|Oct 20, 2020
Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy.

Min Yue Zhang, George A Calin, Kit San Yuen

Pageof 3

Frequent Collaborators

3 joint publications

Yok-Lam Kwong

3 joint publications

Jorge J Castillo

3 joint publications

Anna Waszczuk-Gajda

2 joint publications

Shaji Kumar